{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:21:23Z","timestamp":1794838883713,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.eururo.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:54:25Z","timestamp":1542675265000},"page":"306-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial"],"prefix":"10.1016","volume":"76","author":[{"given":"Kate L.","family":"Mahon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calan","family":"Spielman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Glen","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.11.001_bib0155","series-title":"IARC CancerBase","article-title":"Cancer incidence and mortality worldwide","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.eururo.2018.11.001_bib0160","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.11.001_bib0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.11.001_bib0170","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2018.11.001_bib0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2017.07.007","article-title":"Diagnostic characteristics of lethal prostate cancer","volume":"84","author":"Helgstrand","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2018.11.001_bib0180","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1470-2045(17)30168-7","article-title":"Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial","volume":"18","author":"Chi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0185","doi-asserted-by":"crossref","first-page":"11475","DOI":"10.1016\/S0021-9258(19)50219-8","article-title":"Glutathione S-transferases, structure, regulation, and therapeutic implications","volume":"268","author":"Rushmore","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eururo.2018.11.001_bib0190","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2174\/187152009789056895","article-title":"Glutathione transferases as targets for cancer therapy","volume":"9","author":"Ruzza","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.eururo.2018.11.001_bib0195","doi-asserted-by":"crossref","first-page":"11733","DOI":"10.1073\/pnas.91.24.11733","article-title":"Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis","volume":"91","author":"Lee","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.eururo.2018.11.001_bib0200","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.onc.1202415","article-title":"Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer","volume":"18","author":"Millar","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2018.11.001_bib0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bjc.2011.143","article-title":"Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis","volume":"105","author":"Wu","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2018.11.001_bib0210","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jcb.10740","article-title":"GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer","volume":"91","author":"Nakayama","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.eururo.2018.11.001_bib0215","first-page":"3225","article-title":"A gene hypermethylation profile of human cancer","volume":"61","author":"Esteller","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2018.11.001_bib0220","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1158\/1078-0432.CCR-04-2446","article-title":"Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy","volume":"11","author":"Bastian","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.11.001_bib0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/dna.2011.1311","article-title":"DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer","volume":"31","author":"Delgado-Cruzata","year":"2012","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0230","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ijc.23196","article-title":"Promoter hypermethylation in circulating blood cells identifies prostate cancer progression","volume":"122","author":"Roupret","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2018.11.001_bib0235","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/bjc.2014.463","article-title":"Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer","volume":"111","author":"Mahon","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2018.11.001_bib0240","first-page":"1655","article-title":"Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo","volume":"6","author":"Miyake","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.11.001_bib0245","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0250","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0255","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0260","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.eururo.2018.11.001_bib0265","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eururo.2014.06.024","article-title":"Guidelines for reporting of statistics in European Urology","volume":"67","author":"Vickers","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0270","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0275","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.11.001_bib0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0285","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0290","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.eururo.2018.11.001_bib0295","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2018.11.001_bib0300","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818308558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818308558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T13:22:05Z","timestamp":1662470525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818308558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0302283818308558"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.11.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}